Clinical Trial Update: Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy [Phase 4]

View source ↗

Summary

A Phase 4 head-to-head clinical trial comparing subcutaneous risankizumab to oral apremilast in adults with moderate plaque psoriasis; the trial has completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis
• Psoriasis

Drugs mentioned

• Apremilast (apremilast)
• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Psoriasis | Phase 4 | Status: COMPLETED | Results posted: 2024-04-30